as healthy individuals. However, the clinical relevance of the antibodies is unknown. We
established an enzyme-linked immunosorbent assay with high sensitivity and quantified
serum HER2-AAbs in 100 healthy women, 100 untreated patients with ductal carcinoma in
situ (DCIS), and 500 untreated patients with invasive breast carcinoma (IBC). The
associations between the levels of HER2-AAbs and breast cancer risk, and recurrence-free …